Sharemaestro Newsreel

GRAL Court Deadline: GRAIL, Inc. Investor Deadline in Securities Fraud Class Action is August 4 – Contact BFA Law if You Lost Money

Bleichmar Fonti & Auld LLP has announced a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, which caused a 50.55% stock drop on February 20, 2026, after the …

FDMT|4D Molecular Therapeutics Inc|Price:10.060|Chg%:+0.450

This analysis of 4D Molecular Therapeutics Inc (FDMT) highlights its strong fundamentals, high growth potential, and fair valuation, with a "Buy" rating from multiple analysts and a target price of $28.22. The company, a late-stage biotechnology firm, is advancing therapies for retinal vascular diseases …

Exagen Inc (XGN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Exagen Inc (XGN), detailing its volatility, financial risk, and investment risk. It highlights the company's current risk assessment score, beta value, and various return and volatility metrics over different periods. The assessment also considers the neutral effect …

QTTB|Q32 Bio Inc|Price:15.670|Chg%:+0.460

This article provides a comprehensive stock analysis of Q32 Bio Inc (QTTB) from

Needham raises Neogenomics stock price target on strong Q2 results

Needham has increased its price target for Neogenomics Inc. (NASDAQ:NEO) to $19.00 from $15.00, maintaining a Buy rating, following strong second-quarter 2026 results. The company surpassed revenue and EBITDA consensus estimates, leading management to raise full-year guidance and indicating a potential return to profitability …

Illumina Inc (ILMN) Valuation: PE, PB & Fair Value Analysis

Illumina Inc (ILMN) currently holds a valuation score of 9.61, positioning it 8th out of 199 companies in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 34.86, which is slightly below its recent high but significantly above its recent low. The …

Guardant Health Inc (GH) Institutional Confidence

Guardant Health Inc (GH) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 101.63%, a 4.26% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 504.12K shares, representing 0.53% of …

Neogenomics stock hits 52-week high at 15.61 USD

NeoGenomics Inc. (NEO) stock reached a 52-week high of $15.61 USD, representing a 162.75% increase over the past year. Despite trading above its Fair Value, analysts are optimistic about the company turning profitable this year. This surge follows strong second-quarter 2026 earnings, where NeoGenomics …

PSNL|Personalis Inc|Price:11.860|Chg%:-0.120

Personalis Inc (PSNL) has a relatively healthy financial standing and high growth potential, with its valuation considered fairly valued in the biotechnology industry. Multiple analysts have rated it as a Buy, projecting an upward trend in the medium term despite recent weak market performance. …

Compugen Ltd (CGEN) - Tradingkey

This TradingKey stock analysis provides a comprehensive score for Compugen Ltd (CGEN), highlighting its healthy fundamentals, growth potential, and fair valuation within the Biotechnology & Medical Research industry. The company has growing revenue, institutional buying, and multiple analysts rating it as a "Strong Buy" …

NeoGenomics Reports Second Quarter 2026 Results

NeoGenomics, Inc. announced its second-quarter 2026 results, showing an 11% year-over-year increase in total revenue to $202 million, with robust clinical services revenue growth of 14% driven by a 26% increase in NGS revenue. The company reported a GAAP net income of $2 million …

Danaher Corp Lobbyists, 2002

This OpenSecrets.org page details the lobbyists who represented Danaher Corp in 2002. It lists 13 lobbyists, with 8 having revolving door experience (former federal government employees), including one former member of Congress. The data also specifies the firms employing these lobbyists, primarily Dickstein Shapiro …

CTXR|Citius Pharmaceuticals Inc|Price:0.505|Chg%:-0.012

Citius Pharmaceuticals Inc. (CTXR) has relatively stable fundamentals and high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, the company shows strong fundamentals, and its stock price is expected to trend …

Adaptive Biotechnologies: Q2 Earnings Snapshot

This article provides an earnings snapshot for Adaptive Biotechnologies (NASDAQ: ADPT) for its second quarter. The content appears to be a placeholder or an incomplete article, as it lacks any financial data, results, or detailed information beyond the title.

Illumina Inc (ILMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Illumina Inc (ILMN), detailing its current price momentum score of 3.44 and suggesting it's suitable for range-bound swing trading between resistance at $203.15 and support at $178.79. It evaluates various technical indicators like MACD, RSI, and moving …

FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC.

FOXO Technologies Inc.'s subsidiary, Vector BioSource, Inc., has signed a definitive agreement to acquire four U.S.-based blood collection centers from Grifols Bio Supplies, Inc. This acquisition aims to provide Vector with a proprietary source of bio-products, strengthen its supply chain, and expand its market …

LYEL|Lyell Immunopharma Inc|Price:13.000|Chg%:+0.040

TradingKey provides a comprehensive stock analysis for Lyell Immunopharma Inc (LYEL), highlighting its relatively healthy fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. The company, a late-stage clinical entity developing CAR T-cell therapies, has high institutional ownership and …

Gamco Investors INC. ET AL Boosts Stock Holdings in NeoGenomics, Inc. $NEO

Gamco Investors INC. ET AL significantly increased its stake in NeoGenomics, Inc. by 525% in the first quarter, now holding 100,000 shares valued at $742,000. This move comes as NeoGenomics reported better-than-expected Q2 earnings and raised its fiscal 2026 revenue guidance, despite ongoing concerns …

Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for

Analysts expect Qiagen (QGEN) to report a year-over-year decline in earnings and lower revenues for the quarter ended June 2026, with an expected earnings report date of August 5. The Zacks Earnings ESP for Qiagen is negative (-0.28%) and combined with a Zacks Rank …

SYRE|Spyre Therapeutics Inc|Price:99.940|Chg%:-0.100

This article provides a comprehensive stock analysis of Spyre Therapeutics Inc. (SYRE), highlighting its relatively weak fundamentals but high growth potential, fair valuation, and strong institutional ownership. It details the company's clinical-stage biotechnology focus on inflammatory bowel disease (IBD) and other immune-mediated diseases, outlining …

OPKO Health (NASDAQ:OPK) Reaches New 52-Week High - Here's Why

OPKO Health (NASDAQ:OPK) shares recently hit a new 52-week high after reporting second-quarter results that significantly beat expectations. The company narrowed its adjusted loss and saw revenue rise 4.3% year over year, leading management to raise its 2026 revenue outlook. Despite these positive developments …

ZBIO|Zenas Biopharma Inc|Price:32.290|Chg%:-0.530

Zenas Biopharma Inc (ZBIO) is rated with a strong fundamental health and high growth potential, with its valuation considered fairly valued. Institutional ownership is very high, and analysts have issued "Strong Buy" ratings with a target price indicating significant upside. The company is in …

PRQR|ProQR Therapeutics NV|Price:1.755|Chg%:+0.025

This article provides a comprehensive stock analysis of ProQR Therapeutics NV (PRQR), highlighting its healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes strong institutional ownership and a "Buy" rating from analysts with a target price …

Natera Inc (NTRA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Natera Inc (NTRA), detailing its current risk score, beta value, and various volatility and drawdown metrics. Natera Inc holds a risk assessment score of 8.37, ranking 12th in the Healthcare Providers & Services industry, with a beta …

Qiagen (QGEN) Projected to Post Quarterly Earnings on Wednesday

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …

Icon PLC (ICLR) Lags Q2 Earnings Estimates

NeoGenomics (NASDAQ:NEO) Hits New 1-Year High After Better-Than-Expected Earnings

Mettler-Toledo (MTD) Q2 Earnings: What To Expect

BillionToOne: The Guidance Looks Conservative, The Price Does Not (NASDAQ:BLLN)

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

IDEXX Laboratories (IDXX) Could Be 20% Below Fair Value On Its Diagnostics Growth Story

Wall Street's Insights Into Key Metrics Ahead of Guardant Health (GH) Q2 Earnings

Guardant Health (GH) Q2 Earnings Report Preview: What To Look For

OPKO Health gives back 17% after sharp post-earnings surge (OPK:NASDAQ)

Why NeoGenomics (NEO) Stock Is Up Today